Urinary Tract Biopsy Correlates Urothelial Carcinoma Diagnosis
By LabMedica International staff writers Posted on 28 Sep 2017 |

Image: Histopathology of transitional carcinoma of the urinary bladder from a transurethral biopsy. This exophytic papillary tumor shows multiple finger-like projections lined by multiple layers of urothelium (transitional epithelium) (Photo courtesy of Pathpedia).
Urothelial carcinoma (UCC), also known as transitional cell carcinoma (TCC) is a type of cancer that typically occurs in the urinary system. It is the most common type of bladder cancer and cancer of the ureter.
UCC is the second most common type of kidney cancer, but accounts for only five to 10% of all primary renal malignant tumors. UCC arises from the transitional epithelium, a tissue lining the inner surface of these hollow organs. Transitional cell carcinoma (TCC) accounts for more than 95% of urothelial tumors of the upper urinary tract.
Scientists at the University of Chicago (Chicago, IL, USA) searched their Department of Pathology archive for all cases of upper urothelial tract biopsies and washings between the years 2005 and 2015 that had nephroureterectomy for urothelial carcinoma. In all, 126 patients met the inclusion criteria. They considered cytology diagnoses of either urothelial cancer or “suspicious for urothelial cancer” to be positive. They compared the concordance between combined biopsy and washing, and then compared biopsy and washing diagnoses with the presence of carcinoma on resection.
The team found that from the 126 patients who had resection, only 72 patients had prior diagnostic material. Of those, 33 (26%) had combined biopsy and washing, 26 (21%) had biopsy only, and 13 (10%) had washing only. Among the patients who had had both procedures, 15 (45%) of the diagnoses were concordant as indicated by positive biopsy and cytology, and the final resection specimen revealed urothelial carcinoma. One patient, who was considered concordant, had negative results for both procedures but had urothelial carcinoma on resection.
The scientists found that among the 17 discordant combined biopsy and cytology cases, 11 had positive biopsy with negative washing, four had negative biopsy with positive washing and for two cases, neither biopsy nor washing was diagnostic. Among the 11 positive biopsies with negative washing, five were low-grade papillary urothelial cancer, four were high-grade papillary urothelial cancer, one was urothelial cancer in situ, and one was high-grade urothelial cancer suspicious for invasion.
Providers often obtain biopsies and cytology washings of the upper urinary tract to help them diagnose urothelial cancer, but may have only one procedure performed. Shiraz Fidai, MD, and Tatjana Antic, MD, co-authors of the study, said, “Overall, based on our data, both biopsies and washings of the upper tract (83% for biopsies and 59% for washings) are appropriate in diagnosing urothelial cancer. However, biopsies are more suitable for diagnosing low-grade papillary urothelial cancer when compared with cytology. Size and multifocality of the urothelial cancer of the upper urinary tract plays a significant role in obtaining an adequate specimen for either diagnosis or grading.” The study was presented at the Annual Meeting of the American Society for Clinical Pathology (ASCP), held September 6-8, 2017, in Chicago, IL, USA.
Related Links:
University of Chicago
UCC is the second most common type of kidney cancer, but accounts for only five to 10% of all primary renal malignant tumors. UCC arises from the transitional epithelium, a tissue lining the inner surface of these hollow organs. Transitional cell carcinoma (TCC) accounts for more than 95% of urothelial tumors of the upper urinary tract.
Scientists at the University of Chicago (Chicago, IL, USA) searched their Department of Pathology archive for all cases of upper urothelial tract biopsies and washings between the years 2005 and 2015 that had nephroureterectomy for urothelial carcinoma. In all, 126 patients met the inclusion criteria. They considered cytology diagnoses of either urothelial cancer or “suspicious for urothelial cancer” to be positive. They compared the concordance between combined biopsy and washing, and then compared biopsy and washing diagnoses with the presence of carcinoma on resection.
The team found that from the 126 patients who had resection, only 72 patients had prior diagnostic material. Of those, 33 (26%) had combined biopsy and washing, 26 (21%) had biopsy only, and 13 (10%) had washing only. Among the patients who had had both procedures, 15 (45%) of the diagnoses were concordant as indicated by positive biopsy and cytology, and the final resection specimen revealed urothelial carcinoma. One patient, who was considered concordant, had negative results for both procedures but had urothelial carcinoma on resection.
The scientists found that among the 17 discordant combined biopsy and cytology cases, 11 had positive biopsy with negative washing, four had negative biopsy with positive washing and for two cases, neither biopsy nor washing was diagnostic. Among the 11 positive biopsies with negative washing, five were low-grade papillary urothelial cancer, four were high-grade papillary urothelial cancer, one was urothelial cancer in situ, and one was high-grade urothelial cancer suspicious for invasion.
Providers often obtain biopsies and cytology washings of the upper urinary tract to help them diagnose urothelial cancer, but may have only one procedure performed. Shiraz Fidai, MD, and Tatjana Antic, MD, co-authors of the study, said, “Overall, based on our data, both biopsies and washings of the upper tract (83% for biopsies and 59% for washings) are appropriate in diagnosing urothelial cancer. However, biopsies are more suitable for diagnosing low-grade papillary urothelial cancer when compared with cytology. Size and multifocality of the urothelial cancer of the upper urinary tract plays a significant role in obtaining an adequate specimen for either diagnosis or grading.” The study was presented at the Annual Meeting of the American Society for Clinical Pathology (ASCP), held September 6-8, 2017, in Chicago, IL, USA.
Related Links:
University of Chicago
Latest Pathology News
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
- Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease
- Serum Uromodulin Could Indicate Acute Kidney Injury in COVID-19 Patients
- AI Model Reveals True Biological Age From Five Drops of Blood
- First-Of-Its-Kind AI Tool Visualizes Cell’s ‘Social Network’ To Treat Cancer
- New Test Diagnoses High-Risk Childhood Brain Tumors
- Informatics Solution Elevates Laboratory Efficiency and Patient Care
- Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread
- New AI Tool Outperforms Previous Methods for Identifying Colorectal Cancer from Tissue Sample Analysis
- New Technique Predicts Aggressive Tumors Before They Metastasize
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more
New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
Drug-induced kidney injury, also known as nephrotoxicity, is a prevalent issue in clinical practice, occurring when specific medications at certain doses cause damage to the kidneys. Nephrotoxicity can... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read moreCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreInnovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more